Amphastar Pharmaceuticals Inc AMPH

Healthcare

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

NDAQ:AMPH - Post by User

Amphastar Pharmaceuticals Inc

Bullboard Posts

Next >>

Post by AviseAnalyticson Mar 13, 2023 9:32am

81 Views

Post# 35334386

AMPHASTAR: NEW FDA APPROVAL OPENS A FLOODGATE OF OPPORTUNITI

$AMPH

Excited to share an article about Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation and intranasal products.

Amphastar recently received approval for its New Drug Application (NDA) for naloxone hydrochloride nasal spray 4mg - this is expected to strengthen its already diversified product portfolio further and bring in even more revenue opportunities for the Company.

Read on to know more:

https://www.aviseanalytics.com/amphastar-new-fda-approval-opens-a-floodgate-of-opportunities/

Bullboard Posts

Next >>

Viva Gold brings new drill program and updated PEA to Nevada project